Legend Biotech (LEGN) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Legend Biotech (LEGN) Net Income towards Common Stockholders Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 18.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 92.37% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Legend Biotech | 7.11 Bn | 6.46 Bn | 129.70 Mn | 45.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.50% |
| Dec 31, 2025 | 47.70% |
| Sep 30, 2025 | 69.31% |
| Jun 30, 2025 | -582.66% |
| Mar 31, 2025 | -68.78% |
| Dec 31, 2024 | 33.27% |
| Sep 30, 2024 | -101.46% |
| Jun 30, 2024 | 90.86% |
| Mar 31, 2024 | 46.66% |
| Dec 31, 2023 | 34.83% |
| Sep 30, 2023 | 26.78% |
| Jun 30, 2023 | -3.05% |
| Mar 31, 2023 | -247.18% |
| Dec 31, 2022 | -53.82% |
| Sep 30, 2022 | 31.90% |
| Jun 30, 2022 | -211.97% |
| Mar 31, 2022 | -35,570.18% |
| Dec 31, 2021 | -52.76% |
| Sep 30, 2021 | -87.47% |
| Jun 30, 2021 | 227.95% |